On June 9, 2023 NovalGen Ltd ("NovalGen"), a biopharmaceutical company developing disruptive therapies, based on a proprietary autoregulation (AR) platform, reported the presentation of preclinical data on this novel technology in two separate indications at the International Society on Thrombosis and Haemostasis Congress (ISTH), 24-28 June, 2023 in Toronto and the Immuno-Oncology Summit Boston 2023, 7-9 August, 2023 in Boston (Press release, NovalGen, JUN 9, 2023, View Source [SID1234633763]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to be showcasing our proprietary platform, which has the potential to improve the safety profile and therapeutic index of a range of immunotherapies. Preclinical data with NVG-444 shows a reduction in thrombotic complications with a bispecific Factor VIII mimetic. These data will be presented in an oral presentation at ISTH. The AR platform is target agnostic as illustrated by its application to an extended half-life T cell engager (TCE) targeting ROR1, resulting in a dramatic reduction in toxicity, thus addressing the "Achilles heel" of TCEs allowing more patients to benefit from this off the shelf, T cell activating technology. The AR technology can be applied to a wide range of immunotherapies and heralds a new and exciting class of self-regulating drugs that respond to biological cues to avoid life-threatening toxicities," said Professor Amit Nathwani, Founder and CEO of NovalGen.

Both abstracts will be delivered as oral presentations at the conferences.

Abstracts to be presented:

Conference: ISTH 2023 Congress
Abstract Title: Thrombin-mediated autoregulation restores sensitivity to the coagulation feedback loop and reduces the risk of prothrombotic events associated with FVIII mimetic antibodies.

Abstract Presentation Number: OC 69.1

Session Title: Hemophilia – Novel therapies II

Session Date: Wednesday, 28 June, 2023
Presentation Time: 10:15 am – 10:30 am

Presenting Author: Vincent Muczynski

Conference: Immuno-Oncology Summit Boston 2023
Abstract Title: NVG-222: A ROR1-Targeting T Cell Engager with Integral Autoregulating Capability Designed to Reduce the Risk of Serious Adverse Events Related to T Cell Activation

Session Title: Bispecific Antibodies for Cancer Immunotherapy: Overcoming Obstacles to Efficacy

Session Date: Tuesday, 8 August, 2023

Presentation Time: 8:05am – 8:35am

Presenting Author: David Granger